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Objectives. Abnormalities of posture represent one of the main features of Parkinson’s disease (PD). Among them, camptocormia
has been considered as rare in PD. We investigated frequency and clinical features of camptocormia in PD patients. Methods.
153 PD patients (mean 68.5 ± 10.7 years old, duration 5.9 ± 2.4 years) outpatiently recruited. After neurologic examination,
patients were rated on the Uniﬁed PD Rating Scale motor scale (UPDRS Part III), minimental state examination (MMSE). Also
we evaluated patients with camptocormia by MRI. Of the 153 PD patients, 27 had camptocormia (mean age, 67.9 ± 7.9 years old;
diseaseduration,6.1±3.9years).Forfurtherevaluation,werecruitedage-andsex-matched27PDpatientswithoutcamptocormia
(11 men and 16 women; mean age ± SD, 69.2 ± 10.1 years, duration 6.0 ± 2.7 years) These selected 54 patients completed several
self-assessments. Lumbar and thoracic paraspinal muscles were studied by EMG. Results. There were no signiﬁcant diﬀerences in
age, duration, severity, and drug dose between patients with and without camptocormia. Analysis of NMSS subitems indicated
that PD patients tended to show lower scores for sleep/fatigue, attention/memory, and miscellaneous items. Conclusions. We found
signiﬁcant diﬀerences concerning nonmotor signs and symptoms evaluated by FAB, PDQ-8, FSQ, VAS-F, and NMSS between
patients with and without camptocormia. Our ﬁndings indicate that camptocormia is a relatively common sign in PD and
that patients with camptocormia scores on the PDQ-8 compared with PD patients without camptocormia. This suggests that
improvements in camptocormia of PD patients may improve their QOL.
1.Introduction
Parkinson’s disease (PD) may involve skeletal abnormali-
ties including extreme neck ﬂexion (“dropped head”) and
truncal ﬂexion (camptocormia) [1]. Camptocormia in PD is
deﬁned by marked anteroﬂexion of the trunk, which abates
in the recumbent position, with no or minimal response to
levodopa [1–4]. The condition is exacerbated by walking and
is relieved by sitting, lying in the supine position or by voli-
tionally extending the trunk when the patient leans against
a wall or a table. Although early reports often attributed
camptocormia to a conversion disorder, it is now accepted as
an axial feature of Parkinson’s disease [5–7]. However, pre-
vious studies found no diﬀerences between the parkinsonian
clinicalsignsofPDpatientswithandwithoutcamptocormia,
but Bloch et al. and Tiple et al. reported that there were
diﬀerences in terms of disease duration and severity [6–12].
Magneticresonanceimaging(MRI)andsingle-photonemis-
sion computed tomography (SPECT) ﬁndings of the brain
with dopamine transporters do not diﬀer for PD patients
with and without camptocormia [7, 8]. Two attempts have
apparently been made to explain the mechanisms underlying
camptocormia [6]. The ﬁrst considers camptocormia to be
primarily a dystonia due to a disorder of the striatum [8, 9].
The other theory relates camptocormia to peripheral mecha-
nismsspeciﬁcallyduetomyopathyoftheantigravity muscles
associated with trunk extension [13]. This is supported
by ﬁndings of myopathic changes in paraspinal muscles.
However, the validity of prior reports has been limited by
small sample sizes and short follow-ups [8–16]. Availability
of more information on camptocormia in PD would help to
improve patients‘ quality of life (QOL). In this epidemiolog-
ical and clinical study of a large outpatient population of 153
consecutive PD patients, we investigated the prevalence of2 Parkinson’s Disease
camptocormia in PD, the relationship of camptocormia with
theclinical,especiallynonmotor,featuresofPDandthepres-
ence of possible risk factors for developing camptocormia.
2. Methods
Approval by the central ethics committee for the full study
was initially obtained via the research ethics committee.
We reviewed 153 PD patients (mean age 68.5 ± 10.7y e a r s
old, disease duration 5.9 ± 2.4 years) who sequentially
consulted our clinic in 2005 and diagnosed 27 patients with
camptocormia. The diagnosis of PD was made according
to the UK Brain Bank Criteria [17]. Camptocormia was
deﬁned as an anterior ﬂexion of the thoracolumbar spine of
45◦ or more appearing in orthostatism or during gait and
disappearing in the recumbent position [15]. We excluded
patients with scoliosis. We evaluated patients in the oﬀ and
oncondition.Weexcludedpatientswithisolatedneckﬂexion
(“head drop syndrome”) because these patients might have
been diagnosed with other disorders including multiple
systemic atrophy (MSA) [8, 17]. We excluded also patients
with a combination of camptocormia and head drop. All
patients had brain MRIs. MRIs were performed with a 3.0
T system (Achieva; Philips Medical Systems, Eindhoven,
The Netherlands) using a standard head coil. To exclude
other neurological diseases, sagittal T1-weighted inversion
recovery (TE/TR = 2000/20msec, TI = 900msec) images
with acquisition matrix 256 × 256, ﬁeld of view (FOV) 24 ×
24cm and axial-oblique, parallel to the intercommissural
plane and liquid attenuated inversion recovery (TE/TR =
11000/125msec, TI = 2000msec). T2-weighted spin echo
(SE) (TE/TR = 4931/80msec) images were acquired with
4mm slice thickness, acquisition matrix 512×256, and FOV
24 × 18cm. MRIs of the thoracolumbar spine were also
performed to exclude abnormalities in that area. Lumbar
and thoracic paraspinal muscles were studied by EMG at
the levels T3 to T10, and L1 to S4. Additional spinal MRIs
were conducted, but we could not ﬁnd abnormal ﬁndings
suggesting focal fatty changes in muscles or increased muscle
bulks. Statistical analysis was performed using JMP version
5 package (SAS institute Japan, Tokyo). Unless otherwise
speciﬁed, all data are expressed as means ± SD. Diﬀerences
between groups were examined by the t test. P values <.05
were considered statistically signiﬁcant.
3. Results
Of the 153 PD patients, 27 had camptocormia (mean age,
67.9 ± 7.9 years old; disease duration, 6.1 ± 3.9y e a r s ) .A l l
PD patients with camptocormia exhibited markedly ﬂexed
posture when standing or walking, but were able to sit erect,
and were able to extend their trunk fully when facing a
wall, straightening their back against it, or lying down in
the supine position (Figure 1). Unlike patients with dystonic
disorders, these patients have no access to sensory tricks
[18]. There are no signiﬁcant diﬀerences between patients
with and without camptocormia concerning age, duration,
severity, drugs, and drug doses (Table 1). None of the other
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Figure 1: A patient with camptocormia exhibited markedly ﬂexed
posture when standing or walking, but was able to lie down in
supine position.
ﬁndings contradicted the diagnosis of PD obtained with
MRI.
For further evaluation, we recruited age- and sex-
matched 27 PD patients without camptocormia (11 men and
16 women; mean age ± SD, 69.2 ± 10.1 years) (Table 1).
After neurologic examination, all patients were rated with
theUniﬁedParkinson’sDiseaseRatingScale(UPDRS)motor
examination (UPDRS Part III) [18], and the minimental
state examination (MMSE) [19]. In addition, patients com-
pleted the following self-assessments: the frontal assessment
battery (FAB) [20], Parkinson’s Disease Questionnaires-8
(PDQ-8, a speciﬁc instrument for the assessment of health-
related quality of life in PD) [21], the hospital anxiety and
depressionscale(HADS)[22],thefatiguescalequestionnaire
(FSQ) [23], a fatigue visual analogue scale (VAS-F, 0 (the
worst imaginable fatigue state) to 100 (no fatigue at all) [24],
PD sleep scale (PDSS) [25], and the nonmotor symptom
assessment scale (NMSS) for PD [26, 27].
There were no signiﬁcant diﬀerences in age, duration,
severity, and drug dose between patients with and without
camptocormia,butthereweresigniﬁcantintermsofthetotal
scores for FAB, PDQ-8, FSQ, VAS-F, and NMSS. Analysis
of NMSS subitems indicated that PD patients tended to
show lower scores for sleep/fatigue, attention/memory, and
miscellaneous items (pain, taste, smell, weight loss, and
excessive sweating).Parkinson’s Disease 3
Table 1: Demographic and clinical details of Parkinson’s disease patients with and without camptocormia, and controls.
Controls PD PD with camptocormia PD without camptocormia
Number 27 153 27 27
mean age (±sd) (years) 67.4 ± 8.96 8 .5 ±10.76 9 .2 ±10.16 7 .9 ±7.9
sex (m) 70 11 11
mean duration of disease (years) 5.9 ±2.46 .0 ±2.76 .1 ±3.9
drugs (levodopa equivalent doses (mg), (mean ± sd)) 432 ±212 440 ±221 427 ±203
Hohen-Yahr staging (mean ± sd) 3.0 ±0.73 .1 ±0.53 .1 ±1.6
UPDRS (Part III) (mean ± sd) 34.0 ±16.03 0 .4 ±5.33 2 .5 ±5.1
MMSE (mean) 28.6 27.8 27.6 27.9
FAB (mean ± sd) 16.2 ± 0.81 5 .1 ±1.51 3 .7 ±1.6 #,∗
PDQ-8 (mean ± sd) 16.0 ±6.12 0 .4 ±4.6 #,∗
HADS-depression (mean ± sd)without depression 84 .6 ±3.48 .6 ±5.4 # 8.3 ±5.1 #
HADS-anxiety (mean ± sd) without anxiety 11 5.9 ±4.38 .0 ±4.88 .8 ±6.4
FSQ (mean ± sd) 2.4 ±0.84 .1 ±1.3# 4.8 ±1.0 #,∗
VAS-F (mean ± sd) 30.8 ±10.24 8 .0 ±18.5 # 62.1 ±17.8 #,∗
PDSS (mean ± sd) 120.0 ± 14.87 0 .4 ±26.0 # 69.5 ±17.3 #
NMSS (mean ± sd) 46.5 ±21.15 5 .7 ±15.5∗
#comparing with controls.
∗comparing with PD without camptocormia.
4. Discussion
The 17% prevalence of camptocormia in our series is higher
than that reported in previous studies [6, 14, 28], and is
probably related to diﬀerences in the clinical features of the
study population. Since we excluded patients who might
have parkinsonism other than PD, such as MSA, all our
patients had the distinctive clinical features of PD. Our series
of 27 patients who all met the criteria for camptocormia,
that is, marked ﬂexion of the thoracolumbar spine, which
is most prominent while standing and walking and relieved
in the supine position, illustrates the broad spectrum of
musculoskeletal and neurologic etiologies of this disorder.
The pathogenesis of camptocormia in PD patients is not
known [29]. Although some investigators insist that ﬂexion
of the neck (dropped head) can also be seen in patients with
idiopathic PD, this feature seems to be typically present in
patients with multiple system atrophy [30, 31]. In addition
to PD, other causes of camptocormia include dystonia and
extensor truncal myopathy [9, 13]. Sch¨ abitz. [12]c o n d u c t e d
detailedinvestigationsincludingEMG,neuroimagingstudies
ofthespine,andmusclebiopsyoffourparkinsonianpatients
with camptocormia and found that the pathologic ﬁndings
were consistent with focal myopathy of the paraspinal
muscles. Because we did not ﬁnd any myopathic changes by
EMG, we can rule out the occurrence of these disorders.
Djaldetti et al.’s [6] report deals with eight PD patients
who developed camptocormia and found no evident corre-
lation between the severity of camptocormia and levodopa
treatment. This was reconﬁrmed by the results of our study.
In some patients the camptocormia posture improved, and
in others it was unchanged or even aggravated following
levodopa administration. Djaldetti raised the possibility that
camptocormia might represent either a rare type of dystonia
or an extreme form of rigidity. However, we did not ﬁnd
any evidence of “sensory tricks” used by our patients. In
addition, we could not ﬁnd any radiologic features that
could diﬀerentiate PD patients with from those without
camptocormia. The observation that camptocormia can be
associated with lenticular lesions [32] suggests that the stria-
tumandpallidumplay animportant rolein the maintenance
of axial posture. In general, however, abnormal intensities in
the basal ganglia suggest the possible presence of MSA rather
than PD. Since we excluded patients with MSA, patients with
abnormal intensities in the basal ganglia may also have been
excluded [33–35]. MRI scans of the thoracolumbar spine of
our patients showed only degenerative changes.
This systematic assessment of camptocormia in a large
sample of PD patients has yielded valid assumptions that
provide more information on the relationship between
camptocormia and the clinical features of PD. We could not
ﬁnd any diﬀerences in severity, duration, L-dopa treatment
duration,anddailydoseorthepresenceofdementiabetween
patients with and without camptocormia. In addition, age at
the clinical onset of PD, the unilateral/bilateral distribution
of symptoms at the onset of PD and at the time of the study,
and the development of L-dopa-related motor complications
did not signiﬁcantly diﬀer for patients with and without
camptocormia. The lack of correlation between the degree of
camptocormia and clinical and treatment-related variables
could imply that the pathophysiology of camptocormia
involves additional, nondopaminergic mechanisms. In this
regard, we found signiﬁcant diﬀerences in nonmotor signs
and symptoms evaluated by FAB, PDQ-8, FSQ, VAS-F, and
NMSS between patients with and without camptocormia.
Theseassessmentscalesevaluatefatigue,frontalfunctionand
quality of life [6]. Djaldetti et al. found that three patients
reported worsening of camptocormia with fatigue. For
clinical use, fatigue is best deﬁned as diﬃculty in initiating or
sustaining voluntary activities. Disorders of neuromuscular4 Parkinson’s Disease
junction transmission and metabolic diseases cause muscle
fatigability, which is characterized by failure to sustain the
force of muscle contraction (peripheral fatigue). Fatigue is
also seen in diseases that aﬀect the central nervous system,
which is characterized by failure to sustain attention or to
complete mental tasks (central fatigue) [36, 37]. Fatigue in
multiple sclerosis (MS) may be associated with frontal cortex
andbasalgangliadysfunctionwhichcanresultfromdemyeli-
nation of the frontal white matter [38]. These relationships
between fatigue severity and existence of camptocormia
suggest that development of camptocormia may have some
relationship with frontal lobe dysfunction in PD. In support
of this hypothesis, our results show that PD patients with
camptocormia had lower scores for NMSS subitems related
to fatigue, attention and memory, which are thought to
be frontal lobe functions [26, 27, 39, 40]. P Clinical and
neuroimagingﬁndingshavesuggestedthatthefrontallobeof
PD patients can be considered to be somewhat dysfunctional
[8, 41]. This notion seems to support our hypothesis.
Our ﬁndings indicate that camptocormia is a relatively
common sign in PD and that patients with camptocormia
scores on the PDQ-8 compared with PD patients without
camptocormia. This suggests that improvements in camp-
tocormia of PD patients may improve their QOL. How-
ever, present therapeutic regimens, including drug therapy,
surgical therapy and rehabilitation, have limited eﬀect on
camptocormia. Since we believe that the pathogenesis of
camptocormia in PD patients may involve a variety of fac-
tors, further study is needed to identify these factors, which
m a yt h e nl e a dt oa ne ﬀective therapy for camptocormia in
PD patients.
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